Merck Eyes Purchase of Biotech Seagen

Merck is eyeing a purchase of cancer-focused biotech Seagen. Pulling off a deal could be tricky given the risk of a regulatory challenge, and it is possible the companies could strike a marketing agreement instead.

Merck is eyeing a purchase of cancer-focused biotech Seagen. Pulling off a deal could be tricky given the risk of a regulatory challenge, and it is possible the companies could strike a marketing agreement instead.

Source: Read More

PAID

Leave a Comment